{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T01:08:52Z","timestamp":1785460132217,"version":"3.56.0"},"reference-count":98,"publisher":"American Veterinary Medical Association (AVMA)","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["javma"],"published-print":{"date-parts":[[2023,5,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n<jats:p>The endocannabinoid system (ECS) is an integral neuromodulatory system involved in neuronal development, synaptic plasticity, and homeostasis regarding immunity, as well as brain and other physiological functions such as anxiety, pain, metabolic regulation, and bone growth. <jats:italic>Cannabis<\/jats:italic> is a plant that contains exogenous cannabinoids, which have the potential for profound interplay within the ECS as enzymatic inhibitors or receptor-mediated interactions. Activation of cannabinoid receptors leads to various intracellular signaling processes that are involved in cellular functions, but those interactions are diverse due to different affinities of each cannabinoid with relevant receptors. Among the exogenous cannabinoids, cannabidiol (CBD) has drawn attention due to its potential anticancer, antiangiogenic, anti-inflammatory, and antiseizure properties using in vitro and in vivo models. Although scientific evidence is limited in dogs, there appears to be cautious optimism regarding the utilization of CBD in conjunction with other therapeutics for a range of disorders. This review will primarily focus on current scientific research on the efficacy of CBD on seizure, anxiety, osteoarthritis, and atopic dermatitis, following a brief discussion of endo- and exogenous cannabinoids, ECS, their molecular mechanism, and potential side effects in veterinary medicine. Cannabinoid pharmacology and pharmacokinetics will be addressed in the companion Currents in One Health by Schwark and Wakshlag, <jats:italic>AJVR<\/jats:italic>, May 2023.<\/jats:p>","DOI":"10.2460\/javma.23.02.0064","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T19:09:47Z","timestamp":1679598587000},"page":"623-631","source":"Crossref","is-referenced-by-count":11,"title":["The clinical use of cannabidiol and cannabidiolic acid\u2013rich hemp in veterinary medicine and lessons from human medicine"],"prefix":"10.2460","volume":"261","author":[{"given":"Masayasu","family":"Ukai","sequence":"first","affiliation":[{"name":"Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University Veterinary Teaching Hospital, Colorado State University, Fort Collins, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"McGrath","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University Veterinary Teaching Hospital, Colorado State University, Fort Collins, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Wakshlag","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1272","reference":[{"issue":"7","key":"ref1","series-title":"Biol Psychiatry","first-page":"516","article-title":"An introduction to the endogenous cannabinoid system","volume":"79","author":"Lu HC","year":"2016","unstructured":"Lu HC, Mackie K. An introduction to the endogenous cannabinoid system. Biol Psychiatry. 2016;79(7):516-525. doi:10.1016\/j.biopsych.2015.07.028"},{"key":"ref2","series-title":"Pharmacol Res","first-page":"119","article-title":"Cannabidiol, neuroprotection and neuropsychiatric disorders","volume":"112","author":"Campos AC","year":"2016","unstructured":"Campos AC, Foga\u00e7a MV, Sonego AB, Guimar\u00e3es FS. Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacol Res. 2016;112:119-127. doi:10.1016\/j.phrs.2016.01.03326845349"},{"issue":"1","key":"ref3","series-title":"Annu Rev Pharmacol Toxicol","first-page":"101","article-title":"Cannabinoid receptors as therapeutic targets","volume":"46","author":"Mackie K","year":"2006","unstructured":"Mackie K. Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol. 2006;46(1):101-122. doi:10.1146\/annurev.pharmtox.46.120604.14125416402900"},{"key":"ref4","series-title":"Res Vet Sci","first-page":"38","article-title":"Cannabidiol-based natural health products for companion animals: recent advances in the management of anxiety, pain, and inflammation","volume":"140","author":"Yu CHJ","year":"2021","unstructured":"Yu CHJ, Rupasinghe HPV. Cannabidiol-based natural health products for companion animals: recent advances in the management of anxiety, pain, and inflammation. Res Vet Sci. 2021;140:38-46. doi:10.1016\/j.rvsc.2021.08.00134391060"},{"key":"ref5","series-title":"Front Integr Neurosci","first-page":"24","article-title":"Endocannabinoids and heterogeneity of glial cells in brain function","volume":"10","author":"Scheller A","year":"2016","unstructured":"Scheller A, Kirchhoff F. Endocannabinoids and heterogeneity of glial cells in brain function. Front Integr Neurosci. 2016;10:24. doi:10.3389\/fnint.2016.0002427458351"},{"issue":"3","key":"ref6","series-title":"Acta Pharmacol Sin","first-page":"312","article-title":"Brain cannabinoid receptor 2: expression, function and modulation","volume":"38","author":"Chen DJ","year":"2017","unstructured":"Chen DJ, Gao M, Gao FF, Su QX, Wu J. Brain cannabinoid receptor 2: expression, function and modulation. Acta Pharmacol Sin. 2017;38(3):312-316. doi:10.1038\/aps.2016.14928065934"},{"issue":"1","key":"ref7","series-title":"Int J Mol Sci","first-page":"19","article-title":"CB2 receptor in microglia: the guardian of self-control","volume":"22","author":"Komorowska-M\u00fcller JA","year":"2020","unstructured":"Komorowska-M\u00fcller JA, Schm\u00f6le AC. CB2 receptor in microglia: the guardian of self-control. Int J Mol Sci. 2020;22(1):19. doi:10.3390\/ijms2201001933375006"},{"issue":"23","key":"ref8","series-title":"Cell Mol Life Sci","first-page":"4449","article-title":"The CB2 receptor and its role as a regulator of inflammation","volume":"73","author":"Turcotte C","year":"2016","unstructured":"Turcotte C, Blanchet MR, Laviolette M, Flamand N. The CB2 receptor and its role as a regulator of inflammation. Cell Mol Life Sci. 2016;73(23):4449-4470. doi:10.1007\/s00018-016-2300-4"},{"issue":"7","key":"ref9","series-title":"Future Med Chem","first-page":"1333","article-title":"Cannabinoids as novel anti-inflammatory drugs","volume":"1","author":"Nagarkatti P","year":"2009","unstructured":"Nagarkatti P, Pandey R, Rieder SA, Hegde VL, Nagarkatti M. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem. 2009;1(7):1333-1349. doi:10.4155\/fmc.09.9320191092"},{"issue":"1","key":"ref10","series-title":"J Cannabis Res","first-page":"7","article-title":"The biosynthesis of the cannabinoids","volume":"3","author":"Tahir MN","year":"2021","unstructured":"Tahir MN, Shahbazi F, Rondeau-Gagn\u00e9 S, Trant JF. The biosynthesis of the cannabinoids. J Cannabis Res. 2021;3(1):7. doi:10.1186\/s42238-021-00062-433722296"},{"key":"ref11","series-title":"Vet Med (Auckl)","first-page":"45","article-title":"Cannabinoid, terpene, and heavy metal analysis of 29 over-the-counter commercial veterinary hemp supplements","volume":"11","author":"Wakshlag JJ","year":"2020","unstructured":"Wakshlag JJ, Cital S, Eaton SJ, Prussin R, Hudalla C. Cannabinoid, terpene, and heavy metal analysis of 29 over-the-counter commercial veterinary hemp supplements. Vet Med (Auckl). 2020;11:45-55. doi:10.2147\/VMRR.S24871232346530"},{"key":"ref12","series-title":"J Pharm Biomed Anal","first-page":"532","article-title":"Analysis of cannabinoids in commercial hemp seed oil and decarboxylation kinetics studies of cannabidiolic acid (CBDA)","volume":"149","author":"Citti C","year":"2018","unstructured":"Citti C, Pacchetti B, Vandelli MA, Forni F, Cannazza G. Analysis of cannabinoids in commercial hemp seed oil and decarboxylation kinetics studies of cannabidiolic acid (CBDA). J Pharm Biomed Anal. 2018;149:532-540. doi:10.1016\/j.jpba.2017.11.04429182999"},{"issue":"11","key":"ref13","series-title":"Molecules","first-page":"2638","article-title":"(\u2012)-Cannabidiolic acid, a still overlooked bioactive compound: an introductory review and preliminary research","volume":"25","author":"Formato M","year":"2020","unstructured":"Formato M, Crescente G, Scognamiglio M,  (\u2012)-Cannabidiolic acid, a still overlooked bioactive compound: an introductory review and preliminary research. Molecules. 2020;25(11):2638. doi:10.3390\/molecules2511263832517131"},{"issue":"4","key":"ref14","series-title":"Appl Anim Sci","first-page":"489","article-title":"Nutrient concentrations, digestibility, and cannabinoid concentrations of industrial hemp plant components","volume":"36","author":"Kleinhenz MD","year":"2020","unstructured":"Kleinhenz MD, Magnin G, Ensley SM,  Nutrient concentrations, digestibility, and cannabinoid concentrations of industrial hemp plant components. Appl Anim Sci. 2020;36(4):489-494. doi:10.15232\/aas.2020-02018"},{"issue":"1","key":"ref15","series-title":"Sci Rep","first-page":"12753","article-title":"Plasma concentrations of eleven cannabinoids in cattle following oral administration of industrial hemp (Cannabis sativa)","volume":"10","author":"Kleinhenz MD","year":"2020","unstructured":"Kleinhenz MD, Magnin G, Lin Z,  Plasma concentrations of eleven cannabinoids in cattle following oral administration of industrial hemp (Cannabis sativa). Sci Rep. 2020;10(1):12753. doi:10.1038\/s41598-020-69768-432728233"},{"issue":"10","key":"ref16","series-title":"Am J Vet Res","article-title":"Feeding decreases the oral bioavailability of cannabidiol and cannabidiolic acid in hemp oil in New Zealand White rabbits (Oryctolagus cuniculus)","volume":"83","author":"Rooney TA","year":"2022","unstructured":"Rooney TA, Carpenter JW, KuKanich B, Gardhouse SM, Magnin GC, Tully TN. Feeding decreases the oral bioavailability of cannabidiol and cannabidiolic acid in hemp oil in New Zealand White rabbits (Oryctolagus cuniculus). Am J Vet Res. 2022;83(10): ajvr.22.01.0006. doi:10.2460\/ajvr.22.01.000635947680"},{"issue":"7","key":"ref17","series-title":"Br J Pharmacol","first-page":"1344","article-title":"Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects","volume":"163","author":"Russo EB","year":"2011","unstructured":"Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364. doi:10.1111\/j.1476-5381.2011.01238.x21749363"},{"key":"ref18","series-title":"Front Neurol","first-page":"716","article-title":"Dosage related efficacy and tolerability of cannabidiol in children with treatment-resistant epileptic encephalopathy: preliminary results of the CARE-E study","volume":"10","author":"Huntsman RJ","year":"2019","unstructured":"Huntsman RJ, Tang-Wai R, Alcorn J,  Dosage related efficacy and tolerability of cannabidiol in children with treatment-resistant epileptic encephalopathy: preliminary results of the CARE-E study. Front Neurol. 2019;10:716. doi:10.3389\/fneur.2019.0071631333569"},{"key":"ref19","series-title":"Front Neurol","first-page":"759","article-title":"Potential clinical benefits of CBD-rich cannabis extracts over purified CBD in treatment-resistant epilepsy: observational data meta-analysis","volume":"9","author":"Pamplona FA","year":"2018","unstructured":"Pamplona FA, da Silva LR, Coan AC. Potential clinical benefits of CBD-rich cannabis extracts over purified CBD in treatment-resistant epilepsy: observational data meta-analysis. Front Neurol. 2018;9:759. doi:10.3389\/fneur.2018.0075930258398"},{"issue":"5","key":"ref20","series-title":"Life Sci","first-page":"539","article-title":"Chemical constituents of marijuana: the complex mixture of natural cannabinoids","volume":"78","author":"Elsohly MA","year":"2005","unstructured":"Elsohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci. 2005;78(5):539-548. doi:10.1016\/j.lfs.2005.09.01116199061"},{"issue":"9","key":"ref21","series-title":"Leuk Lymphoma","first-page":"1800","article-title":"Enhancing the in vitro cytotoxic activity of Delta9-tetrahydrocannabinol in leukemic cells through a combinatorial approach","volume":"49","author":"Liu WM","year":"2008","unstructured":"Liu WM, Scott KA, Shamash J, Joel S, Powles TB. Enhancing the in vitro cytotoxic activity of Delta9-tetrahydrocannabinol in leukemic cells through a combinatorial approach. Leuk Lymphoma. 2008;49(9):1800-1809. doi:10.1080\/1042819080223918818608861"},{"issue":"3","key":"ref22","series-title":"Blood","first-page":"1214","article-title":"Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway","volume":"105","author":"Powles T","year":"2005","unstructured":"Powles T, te Poele R, Shamash J,  Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway. Blood. 2005;105(3):1214-1221. doi:10.1182\/blood-2004-03-118215454482"},{"issue":"6","key":"ref23","series-title":"Br J Pharmacol","first-page":"1218","article-title":"Cannabidiol inhibits angiogenesis by multiple mechanisms","volume":"167","author":"Solinas M","year":"2012","unstructured":"Solinas M, Massi P, Cantelmo AR,  Cannabidiol inhibits angiogenesis by multiple mechanisms. Br J Pharmacol. 2012;167(6):1218-1231. doi:10.1111\/j.1476-5381.2012.02050.x22624859"},{"issue":"4","key":"ref24","series-title":"Curr Clin Pharmacol","first-page":"281","article-title":"Cannabis-derived substances in cancer therapy-an emerging anti-inflammatory role for the cannabinoids","volume":"5","author":"Liu WM","year":"2010","unstructured":"Liu WM, Fowler DW, Dalgleish AG. Cannabis-derived substances in cancer therapy-an emerging anti-inflammatory role for the cannabinoids. Curr Clin Pharmacol. 2010;5(4):281-287. doi:10.2174\/15748841079335204920925645"},{"issue":"3","key":"ref25","series-title":"JAMA Neurol","first-page":"285","article-title":"GWPCARE6 Study Group. Add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex: a placebo-controlled randomized clinical trial","volume":"78","author":"Thiele EA","year":"2021","unstructured":"Thiele EA, Bebin EM, Bhathal H,  GWPCARE6 Study Group. Add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex: a placebo-controlled randomized clinical trial. JAMA Neurol. 2021;78(3):285-292. doi:10.1001\/jamaneurol.2020.4607"},{"issue":"9","key":"ref26","series-title":"Epilepsia","first-page":"2228","article-title":"Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: results of a long-term open-label extension trial","volume":"62","author":"Patel AD","year":"2021","unstructured":"Patel AD, Mazurkiewicz-Be\u0142dzi\u0144ska M, Chin RF,  Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: results of a long-term open-label extension trial. Epilepsia. 2021;62(9):2228-2239. doi:10.1111\/epi.1700034287833"},{"key":"ref27","series-title":"Epilepsy Behav","first-page":"131","article-title":"Open-label use of highly purified CBD (Epidiolex\u00ae) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes","volume":"86","author":"Devinsky O","year":"2018","unstructured":"Devinsky O, Verducci C, Thiele EA,  Open-label use of highly purified CBD (Epidiolex\u00ae) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes. Epilepsy Behav. 2018;86:131-137. doi:10.1016\/j.yebeh.2018.05.01330006259"},{"issue":"10","key":"ref28","series-title":"Nat Rev Cancer","first-page":"745","article-title":"Cannabinoids: potential anticancer agents","volume":"3","author":"Guzm\u00e1n M","year":"2003","unstructured":"Guzm\u00e1n M. Cannabinoids: potential anticancer agents. Nat Rev Cancer. 2003;3(10):745-755. doi:10.1038\/nrc118814570037"},{"issue":"5","key":"ref29","series-title":"J Clin Invest","first-page":"1359","article-title":"Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells","volume":"119","author":"Salazar M","year":"2009","unstructured":"Salazar M, Carracedo A, Salanueva IJ,  Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J Clin Invest. 2009;119(5):1359-1372. doi:10.1172\/jci3794819425170"},{"issue":"7","key":"ref30","series-title":"Phytother Res","first-page":"1696","article-title":"Evaluation of pharmacokinetics and acute anti-inflammatory potential of two oral cannabidiol preparations in healthy adults","volume":"34","author":"Hobbs JM","year":"2020","unstructured":"Hobbs JM, Vazquez AR, Remijan ND,  Evaluation of pharmacokinetics and acute anti-inflammatory potential of two oral cannabidiol preparations in healthy adults. Phytother Res. 2020;34(7):1696-1703. doi:10.1002\/ptr.665132147925"},{"issue":"2","key":"ref31","series-title":"Br J Pharmacol","first-page":"199","article-title":"The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin","volume":"153","author":"Pertwee RG","year":"2008","unstructured":"Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153(2):199-215. doi:10.1038\/sj.bjp.070744217828291"},{"issue":"9","key":"ref32","series-title":"Mayo Clin Proc","first-page":"1840","article-title":"Clinicians\u2019 guide to cannabidiol and hemp oils","volume":"94","author":"VanDolah HJ","year":"2019","unstructured":"VanDolah HJ, Bauer BA, Mauck KF. Clinicians\u2019 guide to cannabidiol and hemp oils. Mayo Clin Proc. 2019;94(9):1840-1851. doi:10.1016\/j.mayocp.2019.01.00331447137"},{"key":"ref33","series-title":"Seizure","first-page":"189","article-title":"Interaction of cannabidiol with other antiseizure medications: a narrative review","volume":"86","author":"Gilmartin CGS","year":"2021","unstructured":"Gilmartin CGS, Dowd Z, Parker APJ, Harijan P. Interaction of cannabidiol with other antiseizure medications: a narrative review. Seizure. 2021;86:189-196. doi:10.1016\/j.seizure.2020.09.01033541771"},{"key":"ref34","series-title":"Vet J","first-page":"105913","article-title":"Cannabidiol in canine epilepsy","volume":"290","author":"Potschka H","year":"2022","unstructured":"Potschka H, Bhatti SFM, Tipold A, McGrath S. Cannabidiol in canine epilepsy. Vet J. 2022;290:105913. doi:10.1016\/j.tvjl.2022.10591336209995"},{"issue":"8","key":"ref35","series-title":"Prog Neuropsychopharmacol Biol Psychiatry","first-page":"1517","article-title":"Evidence for a potential role for TRPV1 receptors in the dorsolateral periaqueductal gray in the attenuation of the anxiolytic effects of cannabinoids","volume":"33","author":"Campos AC","year":"2009","unstructured":"Campos AC, Guimar\u00e3es FS. Evidence for a potential role for TRPV1 receptors in the dorsolateral periaqueductal gray in the attenuation of the anxiolytic effects of cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(8):1517-1521. doi:10.1016\/j.pnpbp.2009.08.01719735690"},{"issue":"7","key":"ref36","series-title":"Proc Natl Acad Sci USA","first-page":"3655","article-title":"Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human","volume":"97","author":"Mezey E","year":"2000","unstructured":"Mezey E, T\u00f3th ZE, Cortright DN,  Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc Natl Acad Sci USA. 2000;97(7):3655-3660. doi:10.1073\/pnas.97.7.365510725386"},{"issue":"S1","key":"ref37","series-title":"Epileptic Disord","first-page":"10","article-title":"The proposed mechanisms of action of CBD in epilepsy","volume":"22","author":"Gray RA","year":"2020","unstructured":"Gray RA, Whalley BJ. The proposed mechanisms of action of CBD in epilepsy. Epileptic Disord. 2020;22(S1):10-15. doi:10.1684\/epd.2020.113532053110"},{"issue":"7","key":"ref38","series-title":"Br J Pharmacol","first-page":"1479","article-title":"Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes","volume":"163","author":"De Petrocellis L","year":"2011","unstructured":"De Petrocellis L, Ligresti A, Moriello AS,  Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol. 2011;163(7):1479-1494. doi:10.1111\/j.1476-5381.2010.01166.x21175579"},{"key":"ref39","series-title":"Front Pharmacol","first-page":"675128","article-title":"The heat sensing Trpv1 receptor is not a viable anticonvulsant drug target in the Scn1a +\/\u2212 mouse model of Dravet syndrome","volume":"12","author":"Satpute Janve V","year":"2021","unstructured":"Satpute Janve V, Anderson LL, Bahceci D, Hawkins NA, Kearney JA, Arnold JC. The heat sensing Trpv1 receptor is not a viable anticonvulsant drug target in the Scn1a +\/\u2212 mouse model of Dravet syndrome. Front Pharmacol. 2021;12:675128. doi:10.3389\/fphar.2021.675128"},{"key":"ref40","series-title":"Adv Pharmacol","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/bs.apha.2017.04.004","article-title":"Cannabinoid receptor-related orphan G protein-coupled receptors","volume":"80","author":"Irving A","year":"2017","unstructured":"Irving A, Abdulrazzaq G, Chan SLF, Penman J, Harvey J, Alexander SPH. Cannabinoid receptor-related orphan G protein-coupled receptors. Adv Pharmacol. 2017;80:223-247. doi:10.1016\/bs.apha.2017.04.00428826536"},{"key":"ref41","series-title":"Cancer Manag Res","first-page":"147","article-title":"Orphan G protein receptor GPR55 as an emerging target in cancer therapy and management","volume":"5","author":"Leyva-Illades D","year":"2013","unstructured":"Leyva-Illades D, Demorrow S. Orphan G protein receptor GPR55 as an emerging target in cancer therapy and management. Cancer Manag Res. 2013;5:147-155. doi:10.2147\/CMAR.S3517523869178"},{"issue":"2","key":"ref42","series-title":"Cannabis Cannabinoid Res","first-page":"145","article-title":"Anticonvulsive properties of cannabidiol in a model of generalized seizure are transient receptor potential vanilloid 1 dependent","volume":"5","author":"Gray RA","year":"2020","unstructured":"Gray RA, Stott CG, Jones NA, Di Marzo V, Whalley BJ. Anticonvulsive properties of cannabidiol in a model of generalized seizure are transient receptor potential vanilloid 1 dependent. Cannabis Cannabinoid Res. 2020;5(2):145-149. doi:10.1089\/can.2019.0028"},{"key":"ref43","series-title":"Prog Neurobiol","first-page":"102105","article-title":"ATP and adenosine-two players in the control of seizures and epilepsy development","volume":"204","author":"Beamer E","year":"2021","unstructured":"Beamer E, Kuchukulla M, Boison D, Engel T. ATP and adenosine-two players in the control of seizures and epilepsy development. Prog Neurobiol. 2021;204:102105. doi:10.1016\/j.pneurobio.2021.10210534144123"},{"issue":"9","key":"ref44","series-title":"Vet Sci","first-page":"185","article-title":"Effect of cannabidiol (CBD) on canine inflammatory response: an ex vivo study on LPS stimulated whole blood","volume":"8","author":"Gugliandolo E","year":"2021","unstructured":"Gugliandolo E, Licata P, Peritore AF,  Effect of cannabidiol (CBD) on canine inflammatory response: an ex vivo study on LPS stimulated whole blood. Vet Sci. 2021;8(9):185. doi:10.3390\/vetsci8090185"},{"key":"ref45","series-title":"Neuropharmacology","first-page":"108156","article-title":"Cannabidiol anticonvulsant effect is mediated by the PI3K\u03b3 pathway","volume":"176","author":"Lima IVA","year":"2020","unstructured":"Lima IVA, Bellozi PMQ, Batista EM,  Cannabidiol anticonvulsant effect is mediated by the PI3K\u03b3 pathway. Neuropharmacology. 2020;176:108156. doi:10.1016\/j.neuropharm.2020.10815632574650"},{"key":"ref46","series-title":"Neurosci Biobehav Rev","first-page":"166","article-title":"The anticonvulsant effects of cannabidiol in experimental models of epileptic seizures: from behavior and mechanisms to clinical insights","volume":"111","author":"Lazarini-Lopes W","year":"2020","unstructured":"Lazarini-Lopes W, Do Val-da Silva RA, da Silva-J\u00fanior RMP, Leite JP, Garcia-Cairasco N. The anticonvulsant effects of cannabidiol in experimental models of epileptic seizures: from behavior and mechanisms to clinical insights. Neurosci Biobehav Rev. 2020;111:166-182. doi:10.1016\/j.neubiorev.2020.01.01431954723"},{"issue":"pt A","key":"ref47","series-title":"Epilepsy Behav","first-page":"201","article-title":"UAB CBD Program. Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program","volume":"98","author":"Gaston TE","year":"2019","unstructured":"Gaston TE, Bebin EM, Cutter GR, ; UAB CBD Program. Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program. Epilepsy Behav. 2019;98(pt A):201-206. doi:10.1016\/j.yebeh.2019.07.008"},{"issue":"4","key":"ref48","series-title":"Epilepsia","first-page":"857","article-title":"The role of new medical treatments for the management of developmental and epileptic encephalopathies: novel concepts and results","volume":"62","author":"Johannessen Landmark C","year":"2021","unstructured":"Johannessen Landmark C, Potschka H, Auvin S,  The role of new medical treatments for the management of developmental and epileptic encephalopathies: novel concepts and results. Epilepsia. 2021;62(4):857-873. doi:10.1111\/epi.1684933638459"},{"issue":"7","key":"ref49","series-title":"Neurochem Res","first-page":"1939","article-title":"Evaluation of cannabidiol in animal seizure models by the Epilepsy Therapy Screening Program (ETSP)","volume":"42","author":"Klein BD","year":"2017","unstructured":"Klein BD, Jacobson CA, Metcalf CS,  Evaluation of cannabidiol in animal seizure models by the Epilepsy Therapy Screening Program (ETSP). Neurochem Res. 2017;42(7):1939-1948. doi:10.1007\/s11064-017-2287-828478594"},{"issue":"4","key":"ref50","series-title":"Eur J Neurosci","first-page":"1063","article-title":"Dissociable changes in spike and wave discharges following exposure to injected cannabinoids and smoked cannabis in Genetic Absence Epilepsy Rats from Strasbourg","volume":"55","author":"Roebuck AJ","year":"2022","unstructured":"Roebuck AJ, Greba Q, Onofrychuk TJ,  Dissociable changes in spike and wave discharges following exposure to injected cannabinoids and smoked cannabis in Genetic Absence Epilepsy Rats from Strasbourg. Eur J Neurosci. 2022;55(4):1063-1078. doi:10.1111\/ejn.1509633370468"},{"issue":"1","key":"ref51","series-title":"BMC Vet Res","first-page":"148","article-title":"International veterinary epilepsy task force consensus proposal: diagnostic approach to epilepsy in dogs","volume":"11","author":"De Risio L","year":"2015","unstructured":"De Risio L, Bhatti S, Mu\u00f1ana K,  International veterinary epilepsy task force consensus proposal: diagnostic approach to epilepsy in dogs. BMC Vet Res. 2015;11(1):148. doi:10.1186\/s12917-015-0462-126316175"},{"key":"ref52","series-title":"Front Vet Sci","first-page":"939966","article-title":"Safety and efficacy of cannabidiol-cannabidiolic acid rich hemp extract in the treatment of refractory epileptic seizures in dogs","volume":"9","author":"Garcia GA","year":"2022","unstructured":"Garcia GA, Kube S, Carrera-Justiz S, Tittle D, Wakshlag JJ. Safety and efficacy of cannabidiol-cannabidiolic acid rich hemp extract in the treatment of refractory epileptic seizures in dogs. Front Vet Sci. 2022;9:939966. doi:10.3389\/fvets.2022.93996635967998"},{"issue":"11","key":"ref53","series-title":"J Am Vet Med Assoc","first-page":"1301","article-title":"Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy","volume":"254","author":"McGrath S","year":"2019","unstructured":"McGrath S, Bartner LR, Rao S, Packer RA, Gustafson DL. Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy. J Am Vet Med Assoc. 2019;254(11):1301-1308. doi:10.2460\/javma.254.11.130131067185"},{"issue":"pt B","key":"ref54","series-title":"Epilepsy Behav","first-page":"319","article-title":"Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection","volume":"70","author":"Rosenberg EC","year":"2017","unstructured":"Rosenberg EC, Patra PH, Whalley BJ. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection. Epilepsy Behav. 2017;70(pt B):319-327. doi:10.1016\/j.yebeh.2016.11.00628190698"},{"key":"ref55","series-title":"Front Pharmacol","first-page":"359","article-title":"\u03949-THC intoxication by cannabidiol-enriched cannabis extract in two children with refractory epilepsy: full remission after switching to purified cannabidiol","volume":"7","author":"Crippa JAS","year":"2016","unstructured":"Crippa JAS, Crippa ACS, Hallak JEC, Mart\u00edn-Santos R, Zuardi AW. \u03949-THC intoxication by cannabidiol-enriched cannabis extract in two children with refractory epilepsy: full remission after switching to purified cannabidiol. Front Pharmacol. 2016;7:359. doi:10.3389\/fphar.2016.0035927746737"},{"issue":"5","key":"ref56","series-title":"J Vet Emerg Crit Care (San Antonio)","first-page":"573","article-title":"Use of gas chromatography-mass spectrometry for definitive diagnosis of synthetic cannabinoid toxicity in a dog","volume":"29","author":"Kelmer E","year":"2019","unstructured":"Kelmer E, Shimshoni JA, Merbl Y, Kolski O, Klainbart S. Use of gas chromatography-mass spectrometry for definitive diagnosis of synthetic cannabinoid toxicity in a dog. J Vet Emerg Crit Care (San Antonio). 2019;29(5):573-577. doi:10.1111\/vec.12872"},{"issue":"1","key":"ref57","series-title":"Top Companion Anim Med","first-page":"8","article-title":"Marijuana poisoning","volume":"28","author":"Fitzgerald KT","year":"2013","unstructured":"Fitzgerald KT, Bronstein AC, Newquist KL. Marijuana poisoning. Top Companion Anim Med. 2013;28(1):8-12. doi:10.1053\/j.tcam.2013.03.00423796481"},{"issue":"9","key":"ref58","series-title":"Epilepsia","first-page":"1586","article-title":"UAB CBD Program. Interactions between cannabidiol and commonly used antiepileptic drugs","volume":"58","author":"Gaston TE","year":"2017","unstructured":"Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP; UAB CBD Program. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017;58(9):1586-1592. doi:10.1111\/epi.1385228782097"},{"issue":"4","key":"ref59","series-title":"Int J Mol Sci","first-page":"1863","article-title":"Cannabidiol as a potential treatment for anxiety and mood disorders: molecular targets and epigenetic insights from preclinical research","volume":"22","author":"Melas PA","year":"2021","unstructured":"Melas PA, Scherma M, Fratta W, Cifani C, Fadda P. Cannabidiol as a potential treatment for anxiety and mood disorders: molecular targets and epigenetic insights from preclinical research. Int J Mol Sci. 2021;22(4):1863. doi:10.3390\/ijms2204186333668469"},{"issue":"10","key":"ref60","series-title":"Br J Pharmacol","first-page":"1552","article-title":"Single and combined effects of plant-derived and synthetic cannabinoids on cognition and cannabinoid-associated withdrawal signs in mice","volume":"176","author":"Myers AM","year":"2019","unstructured":"Myers AM, Siegele PB, Foss JD, Tuma RF, Ward SJ. Single and combined effects of plant-derived and synthetic cannabinoids on cognition and cannabinoid-associated withdrawal signs in mice. Br J Pharmacol. 2019;176(10):1552-1567. doi:10.1111\/bph.1414729338068"},{"key":"ref61","series-title":"Pharmacol Biochem Behav","first-page":"60","article-title":"Cannabinoids, interoception, and anxiety","volume":"180","author":"Andrade AK","year":"2019","unstructured":"Andrade AK, Renda B, Murray JE. Cannabinoids, interoception, and anxiety. Pharmacol Biochem Behav. 2019;180:60-73. doi:10.1016\/j.pbb.2019.03.00630922834"},{"issue":"2","key":"ref62","series-title":"Psychopharmacology (Berl)","first-page":"239","article-title":"Anxiogenic-like effects of chronic cannabidiol administration in rats","volume":"221","author":"ElBatsh MM","year":"2012","unstructured":"ElBatsh MM, Assareh N, Marsden CA, Kendall DA. Anxiogenic-like effects of chronic cannabidiol administration in rats. Psychopharmacology (Berl). 2012;221(2):239-247. doi:10.1007\/s00213-011-2566-z22083592"},{"issue":"1","key":"ref63","series-title":"J Psychopharmacol","first-page":"121","article-title":"Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report","volume":"25","author":"Crippa JAS","year":"2011","unstructured":"Crippa JAS, Derenusson GN, Ferrari TB,  Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol. 2011;25(1):121-130. doi:10.1177\/026988111037928320829306"},{"issue":"1","key":"ref64","series-title":"Behav Brain Res","first-page":"105","article-title":"Involvement of the prelimbic prefrontal cortex on cannabidiol-induced attenuation of contextual conditioned fear in rats","volume":"207","author":"Lemos JI","year":"2010","unstructured":"Lemos JI, Resstel LB, Guimar\u00e3es FS. Involvement of the prelimbic prefrontal cortex on cannabidiol-induced attenuation of contextual conditioned fear in rats. Behav Brain Res. 2010;207(1):105-111. doi:10.1016\/j.bbr.2009.09.04519800921"},{"issue":"6","key":"ref65","series-title":"Neuropsychopharmacology","first-page":"1219","article-title":"Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-na\u00efve social phobia patients","volume":"36","author":"Bergamaschi MM","year":"2011","unstructured":"Bergamaschi MM, Queiroz RHC, Chagas MHN,  Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-na\u00efve social phobia patients. Neuropsychopharmacology. 2011;36(6):1219-1226. doi:10.1038\/npp.2011.621307846"},{"issue":"4","key":"ref66","series-title":"Neurotherapeutics","first-page":"825","article-title":"Cannabidiol as a potential treatment for anxiety disorders","volume":"12","author":"Blessing EM","year":"2015","unstructured":"Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics. 2015;12(4):825-836. doi:10.1007\/s13311-015-0387-126341731"},{"key":"ref67","series-title":"Eur Neuropsychopharmacol","first-page":"58","article-title":"Cannabidiol enhancement of exposure therapy in treatment refractory patients with social anxiety disorder and panic disorder with agoraphobia: a randomised controlled trial","volume":"59","author":"Kwee CM","year":"2022","unstructured":"Kwee CM, Baas JM, van der Flier FE,  Cannabidiol enhancement of exposure therapy in treatment refractory patients with social anxiety disorder and panic disorder with agoraphobia: a randomised controlled trial. Eur Neuropsychopharmacol. 2022;59:58-67. doi:10.1016\/j.euroneuro.2022.04.00335561538"},{"key":"ref68","series-title":"J Psychiatr Res","first-page":"257","article-title":"Efficacy and acceptability of cannabinoids for anxiety disorders in adults: a systematic review and meta-analysis","volume":"129","author":"Bahji A","year":"2020","unstructured":"Bahji A, Meyyappan AC, Hawken ER. Efficacy and acceptability of cannabinoids for anxiety disorders in adults: a systematic review and meta-analysis. J Psychiatr Res. 2020;129:257-264. doi:10.1016\/j.jpsychires.2020.07.03032827809"},{"issue":"1","key":"ref69","series-title":"Annu Rev Anim Biosci","first-page":"227","article-title":"Scientific validation of cannabidiol for management of dog and cat diseases","volume":"11","author":"Corsato Alvarenga I","year":"2023","unstructured":"Corsato Alvarenga I, Panickar KS, Hess H, McGrath S. Scientific validation of cannabidiol for management of dog and cat diseases. Annu Rev Anim Biosci. 2023;11(1):227-246. doi:10.1146\/annurev-animal-081122-07023636790884"},{"issue":"1","key":"ref70","series-title":"Sci Rep","first-page":"2773","article-title":"Cannabis sativa L","volume":"11","author":"Corsetti S","year":"2021","unstructured":"Corsetti S, Borruso S, Malandrucco L,  Cannabis sativa L. may reduce aggressive behaviour towards humans in shelter dogs. Sci Rep. 2021;11(1):2773. doi:10.1038\/s41598-021-82439-233531559"},{"key":"ref71","series-title":"Front Vet Sci","first-page":"569565","article-title":"The impact of feeding cannabidiol (CBD) containing treats on canine response to a noise-induced fear response test","volume":"7","author":"Morris EM","year":"2020","unstructured":"Morris EM, Kitts-Morgan SE, Spangler DM, McLeod KR, Costa JHC, Harmon DL. The impact of feeding cannabidiol (CBD) containing treats on canine response to a noise-induced fear response test. Front Vet Sci. 2020;7:569565. doi:10.3389\/fvets.2020.56956533195551"},{"issue":"1","key":"ref72","series-title":"J Hered","first-page":"49","article-title":"Isolation and characterization of the canine serotonin receptor 1A gene (htr1A)","volume":"94","author":"van den Berg L","year":"2003","unstructured":"van den Berg L, Versteeg SA, van Oost BA. Isolation and characterization of the canine serotonin receptor 1A gene (htr1A). J Hered. 2003;94(1):49-56. doi:10.1093\/jhered\/esg01312692162"},{"issue":"1","key":"ref73","series-title":"J Neurophysiol","first-page":"503","article-title":"TRPV1 receptor mediates glutamatergic synaptic input to dorsolateral periaqueductal gray (dl-PAG) neurons","volume":"97","author":"Xing J","year":"2007","unstructured":"Xing J, Li J. TRPV1 receptor mediates glutamatergic synaptic input to dorsolateral periaqueductal gray (dl-PAG) neurons. J Neurophysiol. 2007;97(1):503-511. doi:10.1152\/jn.01023.200617065246"},{"issue":"1","key":"ref74","series-title":"Psychopharmacology (Berl)","first-page":"30","article-title":"Anxiolytic-like effects of AP7 injected into the dorsolateral or ventrolateral columns of the periaqueductal gray of rats","volume":"160","author":"Molchanov ML","year":"2002","unstructured":"Molchanov ML, Guimar\u00e3es FS. Anxiolytic-like effects of AP7 injected into the dorsolateral or ventrolateral columns of the periaqueductal gray of rats. Psychopharmacology (Berl). 2002;160(1):30-38. doi:10.1007\/s00213-001-0941-x"},{"issue":"11","key":"ref75","series-title":"CNS Drugs","first-page":"1053","article-title":"A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects","volume":"32","author":"Taylor L","year":"2018","unstructured":"Taylor L, Gidal B, Blakey G, Tayo B, Morrison G. A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs. 2018;32(11):1053-1067. doi:10.1007\/s40263-018-0578-530374683"},{"issue":"6","key":"ref76","series-title":"J Anal Toxicol","first-page":"583","article-title":"Pharmacokinetic profile of \u22069-tetrahydrocannabinol, cannabidiol and metabolites in blood following vaporization and oral ingestion of cannabidiol products","volume":"46","author":"Bergeria CL","year":"2022","unstructured":"Bergeria CL, Spindle TR, Cone EJ,  Pharmacokinetic profile of \u22069-tetrahydrocannabinol, cannabidiol and metabolites in blood following vaporization and oral ingestion of cannabidiol products. J Anal Toxicol. 2022;46(6):583-591. doi:10.1093\/jat\/bkab12435438179"},{"issue":"4","key":"ref77","series-title":"J Anal Toxicol","first-page":"393","article-title":"Safety, pharmacokinetics and pharmacodynamics of spectrum yellow oil in healthy participants","volume":"46","author":"Peters EN","year":"2022","unstructured":"Peters EN, Mosesova I, MacNair L,  Safety, pharmacokinetics and pharmacodynamics of spectrum yellow oil in healthy participants. J Anal Toxicol. 2022;46(4):393-407. doi:10.1093\/jat\/bkab02633710277"},{"issue":"22","key":"ref78","series-title":"Int J Mol Sci","first-page":"8870","article-title":"Cannabidiol for pain treatment: focus on pharmacology and mechanism of action","volume":"21","author":"Mlost J","year":"2020","unstructured":"Mlost J, Bryk M, Starowicz K. Cannabidiol for pain treatment: focus on pharmacology and mechanism of action. Int J Mol Sci. 2020;21(22):8870. doi:10.3390\/ijms2122887033238607"},{"issue":"1","key":"ref79","series-title":"Curr Med Res Opin","first-page":"17","article-title":"Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain","volume":"23","author":"Iskedjian M","year":"2007","unstructured":"Iskedjian M, Bereza B, Gordon A, Piwko C, Einarson TR. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin. 2007;23(1):17-24. doi:10.1185\/030079906x15806617257464"},{"issue":"7","key":"ref80","series-title":"Cureus","first-page":"e26913","article-title":"Efficacy, safety, and regulation of cannabidiol on chronic pain: a systematic review","volume":"14","author":"Villanueva MRB","year":"2022","unstructured":"Villanueva MRB, Joshaghani N, Villa N,  Efficacy, safety, and regulation of cannabidiol on chronic pain: a systematic review. Cureus. 2022;14(7):e26913. doi:10.7759\/cureus.2691335860716"},{"issue":"6","key":"ref81","series-title":"Pain","first-page":"1206","article-title":"Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: a randomized, double-blind, placebo-controlled trial","volume":"163","author":"Vela J","year":"2022","unstructured":"Vela J, Dreyer L, Petersen KK, Arendt-Nielsen L, Duch KS, Kristensen S. Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: a randomized, double-blind, placebo-controlled trial. Pain. 2022;163(6):1206-1214. doi:10.1097\/j.pain.000000000000246634510141"},{"key":"ref82","series-title":"Front Vet Sci","first-page":"165","article-title":"Pharmacokinetics, safety, and clinical efficacy of cannabidiol treatment in osteoarthritic dogs","volume":"5","author":"Gamble LJ","year":"2018","unstructured":"Gamble LJ, Boesch JM, Frye CW,  Pharmacokinetics, safety, and clinical efficacy of cannabidiol treatment in osteoarthritic dogs. Front Vet Sci. 2018;5:165. doi:10.3389\/fvets.2018.0016530083539"},{"issue":"9","key":"ref83","series-title":"Pain","first-page":"2191","article-title":"A randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain","volume":"161","author":"Verrico CD","year":"2020","unstructured":"Verrico CD, Wesson S, Konduri V,  A randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain. Pain. 2020;161(9):2191-2202. doi:10.1097\/j.pain.000000000000189632345916"},{"issue":"9","key":"ref84","series-title":"Animals (Basel)","first-page":"E1505","article-title":"Oral transmucosal cannabidiol oil formulation as part of a multimodal analgesic regimen: effects on pain relief and quality of life improvement in dogs affected by spontaneous osteoarthritis","volume":"10","author":"Brioschi FA","year":"2020","unstructured":"Brioschi FA, Di Cesare F, Gioeni D,  Oral transmucosal cannabidiol oil formulation as part of a multimodal analgesic regimen: effects on pain relief and quality of life improvement in dogs affected by spontaneous osteoarthritis. Animals (Basel). 2020;10(9):E1505. doi:10.3390\/ani10091505"},{"issue":"2","key":"ref85","series-title":"J Am Anim Hosp Assoc","first-page":"81","article-title":"Evaluation of the effect of cannabidiol on naturally occurring osteoarthritis-associated pain: a pilot study in dogs","volume":"57","author":"Mejia S","year":"2021","unstructured":"Mejia S, Duerr FM, Griffenhagen G, McGrath S. Evaluation of the effect of cannabidiol on naturally occurring osteoarthritis-associated pain: a pilot study in dogs. J Am Anim Hosp Assoc. 2021;57(2):81-90. doi:10.5326\/JAAHA-MS-7119"},{"issue":"3","key":"ref86","series-title":"Med Rev Berl","first-page":"251","article-title":"Peripheral mechanisms of chronic pain","volume":"2","author":"Zheng Q","year":"2022","unstructured":"Zheng Q, Dong X, Green DP, Dong X. Peripheral mechanisms of chronic pain. Med Rev Berl. 2022;2(3):251-270. doi:10.1515\/mr-2022-001336067122"},{"key":"ref87","series-title":"Front Vet Sci","first-page":"1036056","article-title":"Evaluation of the efficacy of a cannabidiol and cannabidiolic acid rich hemp extract for pain in dogs following a tibial plateau leveling osteotomy","volume":"9","author":"Klatzkow S","year":"2023","unstructured":"Klatzkow S, Davis G, Shmalberg J,  Evaluation of the efficacy of a cannabidiol and cannabidiolic acid rich hemp extract for pain in dogs following a tibial plateau leveling osteotomy. Front Vet Sci. 2023;9:1036056. doi:10.3389\/fvets.2022.103605636686184"},{"key":"ref88","series-title":"Proceedings of the American College of Veterinary Internal Medicine Forum","article-title":"Evaluating the benefits of cannabidiol for analgesia following surgery for intervertebral disc herniation in dogs","author":"Wright J","year":"2022","unstructured":"Wright J. Evaluating the benefits of cannabidiol for analgesia following surgery for intervertebral disc herniation in dogs. In: Proceedings of the American College of Veterinary Internal Medicine Forum. American College of Veterinary Internal Medicine; 2022."},{"key":"ref89","series-title":"Front Vet Sci","first-page":"915896","article-title":"Distribution of cannabinoid receptors in keratinocytes of healthy dogs and dogs with atopic dermatitis","volume":"9","author":"Chiocchetti R","year":"2022","unstructured":"Chiocchetti R, De Silva M, Aspidi F,  Distribution of cannabinoid receptors in keratinocytes of healthy dogs and dogs with atopic dermatitis. Front Vet Sci. 2022;9:915896. doi:10.3389\/fvets.2022.91589635873682"},{"key":"ref90","series-title":"Front Vet Sci","first-page":"987132","article-title":"Cannabinoid receptors in the inflammatory cells of canine atopic dermatitis","volume":"9","author":"Chiocchetti R","year":"2022","unstructured":"Chiocchetti R, Salamanca G, De Silva M,  Cannabinoid receptors in the inflammatory cells of canine atopic dermatitis. Front Vet Sci. 2022;9:987132. doi:10.3389\/fvets.2022.98713236187821"},{"issue":"3","key":"ref91","series-title":"Biochim Biophys Acta Gen Subj","first-page":"586","article-title":"Identification and characterization of phytocannabinoids as novel dual PPAR\u03b1\/\u03b3 agonists by a computational and in vitro experimental approach","volume":"1863","author":"D\u2019Aniello E","year":"2019","unstructured":"D\u2019Aniello E, Fellous T, Iannotti FA,  Identification and characterization of phytocannabinoids as novel dual PPAR\u03b1\/\u03b3 agonists by a computational and in vitro experimental approach. Biochim Biophys Acta Gen Subj. 2019;1863(3):586-597. doi:10.1016\/j.bbagen.2019.01.00230611848"},{"issue":"4","key":"ref92","series-title":"Vet Dermatol","first-page":"329","article-title":"The effect of a mixed cannabidiol and cannabidiolic acid based oil on client-owned dogs with atopic dermatitis","volume":"33","author":"Loewinger M","year":"2022","unstructured":"Loewinger M, Wakshlag JJ, Bowden D, Peters-Kennedy J, Rosenberg A. The effect of a mixed cannabidiol and cannabidiolic acid based oil on client-owned dogs with atopic dermatitis. Vet Dermatol. 2022;33(4):329-e77. doi:10.1111\/vde.1307735644533"},{"key":"ref93","series-title":"Front Vet Sci","first-page":"645667","article-title":"Feeding cannabidiol (CBD)-containing treats did not affect canine daily voluntary activity","volume":"8","author":"Morris EM","year":"2021","unstructured":"Morris EM, Kitts-Morgan SE, Spangler DM,  Feeding cannabidiol (CBD)-containing treats did not affect canine daily voluntary activity. Front Vet Sci. 2021;8:645667. doi:10.3389\/fvets.2021.645667"},{"key":"ref94","series-title":"Res Vet Sci","first-page":"13","article-title":"Feeding treats containing cannabidiol (CBD) did not alter canine immune response to immunization with a novel antigen","volume":"143","author":"Morris EM","year":"2022","unstructured":"Morris EM, Kitts-Morgan SE, Spangler DM, McLeod KR, Suckow MA, Harmon DL. Feeding treats containing cannabidiol (CBD) did not alter canine immune response to immunization with a novel antigen. Res Vet Sci. 2022;143:13-19. doi:10.1016\/j.rvsc.2021.12.012"},{"issue":"5","key":"ref95","series-title":"Am J Vet Res","first-page":"405","article-title":"Randomized, placebo-controlled, 28-day safety and pharmacokinetics evaluation of repeated oral cannabidiol administration in healthy dogs","volume":"82","author":"Vaughn DM","year":"2021","unstructured":"Vaughn DM, Paulionis LJ, Kulpa JE. Randomized, placebo-controlled, 28-day safety and pharmacokinetics evaluation of repeated oral cannabidiol administration in healthy dogs. Am J Vet Res. 2021;82(5):405-416. doi:10.2460\/ajvr.82.5.40533904801"},{"key":"ref96","series-title":"Front Vet Sci","first-page":"51","article-title":"Preliminary investigation of the safety of escalating cannabinoid doses in healthy dogs","volume":"7","author":"Vaughn D","year":"2020","unstructured":"Vaughn D, Kulpa J, Paulionis L. Preliminary investigation of the safety of escalating cannabinoid doses in healthy dogs. Front Vet Sci. 2020;7:51. doi:10.3389\/fvets.2020.0005132118071"},{"issue":"10","key":"ref97","series-title":"Animals (Basel)","first-page":"E832","article-title":"Single-dose pharmacokinetics and preliminary safety assessment with use of CBD-rich hemp nutraceutical in healthy dogs and cats","volume":"9","author":"Deabold KA","year":"2019","unstructured":"Deabold KA, Schwark WS, Wolf L, Wakshlag JJ. Single-dose pharmacokinetics and preliminary safety assessment with use of CBD-rich hemp nutraceutical in healthy dogs and cats. Animals (Basel). 2019;9(10):E832. doi:10.3390\/ani9100832"},{"key":"ref98","series-title":"Front Vet Sci","first-page":"977457","article-title":"Long-term daily feeding of cannabidiol is well-tolerated by healthy dogs","volume":"9","author":"Bradley S","year":"2022","unstructured":"Bradley S, Young S, Bakke AM,  Long-term daily feeding of cannabidiol is well-tolerated by healthy dogs. Front Vet Sci. 2022;9:977457. doi:10.3389\/fvets.2022.97745736213402"}],"container-title":["Journal of the American Veterinary Medical Association"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/261\/5\/javma.23.02.0064.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/261\/5\/javma.23.02.0064.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/261\/5\/javma.23.02.0064.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T13:02:43Z","timestamp":1741352563000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/261\/5\/javma.23.02.0064.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,1]]},"references-count":98,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.2460\/javma.23.02.0064","relation":{},"ISSN":["0003-1488"],"issn-type":[{"value":"0003-1488","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,1]]}}}